Perry S Eisman

Title: The Innovations of Perry S. Eisman

Introduction

Perry S. Eisman is a notable inventor based in Southampton, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of anxiety and obsessive-compulsive disorders. With a total of two patents to his name, his work has the potential to impact many lives.

Latest Patents

Eisman's latest patents include innovative methods for treating social anxiety disorder. The first patent describes the use of pagoclone, which involves administering specific compounds such as 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone or its optical isomers. This method may also include the administration of a GABA agonist to enhance treatment efficacy. His second patent focuses on methods for treating obsessive-compulsive disorder, utilizing the compound -(-chloro--naphthyridin--yl)--(-methyl--oxo-hexyl)--isoindolinone.

Career Highlights

Eisman is currently associated with Indevus Pharmaceuticals, Inc., where he continues to develop and refine his innovative approaches to mental health treatment. His work is characterized by a commitment to improving therapeutic options for patients suffering from anxiety-related disorders.

Collaborations

Eisman has collaborated with several professionals in his field, including Cathryn M. Clary and Jeroen Van Beek. These partnerships have likely contributed to the advancement of his research and the successful development of his patents.

Conclusion

Perry S. Eisman's contributions to the field of pharmaceuticals, particularly in treating social anxiety and obsessive-compulsive disorders, highlight his innovative spirit and dedication to improving mental health treatments. His patents represent significant advancements that could benefit many individuals facing these challenges.